Neuroprotective Properties of a Standardized Extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertão), as Evaluated by a Parkinson’s Disease Model in Rats

Table 2

Effects of the standardized extract from M. urundeuva (SEMU) on striatal DA and DOPAC levels (ng/g tissue), in the model of Parkinson’s disease in rats.

Group	Dopamine (DA)	DOPAC	DOPAC/DA
6-OHDA; ipsilateral	881.5±108.77^a	825.6±121.2	0.94
6-OHDA; contralateral	2559.0±149.0	1141.0±120.1	0.45
SEMU 10; ipsilateral	1057.0±42.3	831.30±239.8	0.79
SEMU 10; contralateral	2021.0±37.57	1299.0±167.1	0.64
SEMU 20; ipsilateral	1913.0±146.2	208.2±36.2^a,b	0.11
SEMU 20; contralateral	2582.0±280.2^b	304.6±46.6	0.12
SEMU 40; ipsilateral	2450.0±1637^a,b	314.7±12.6^a	0.13
SEMU 40; contralateral	3921.0±221.8	1755.0±172.0	0.45
SO; ipsilateral	3186.0±285.3^b	1556.0±227.7^b	0.49
SO; contralateral	2942.0±204.0	1746.0±196.6	0.59

The standardized extract from M. urundeuva (SEMU: 5, 10, 20, and 40 mg/kg, p.o.) was administered 1 h after the stereotaxic surgery (injection of 6-OHDA or distilled water into the right striatum-SO) and, afterwards, daily for 14 days. After behavioral experiments, all animals were euthanized for the dissection of right and left striata. The results are means ± SEM from 5 to 12 animals. ^a,b𝑃<0.05 versus the contralateral side of each group or versus the SO group (one-way ANOVA and the Newman-Keuls as the post hoc test).